Clinical Effect of Carrilizumab Combined with Paclitaxel and Cisplatin in the Treatment of Advanced Esophageal Cancer
Objective To investigate the clinical efficacy of carrilizumab combined with paclitaxel and cisplatin in the treatment of advanced esophageal cancer.Methods Eighty patients with advanced esophageal cancer admitted to the Xinghua People's Hospital from January 2020 to December 2022 were randomly selected as the study objects,and di-vided into observation group(paclitaxel+cisplatin+karelizumab;n=40)and control group(paclitaxel+cisplatin;n=40)by random number table method.Clinical outcomes,adverse reactions,and quality of life score were compared be-tween the two groups.Results The effective rate of observation group was 95.00%,significantly higher than that of con-trol group 80.00%,and the difference was statistically significant(χ2=4.114,P<0.05).The incidence of adverse reac-tions in observation group was 5.00%,significantly lower than that in control group 20.00%,and the difference was statistically significant(χ2=4.114,P<0.05).The quality of life score in observation group was significantly higher than that of the control group,and the difference was statistically significant(P<0.05).Conclusion Carrilizumab combined with paclitaxel and cisplatin has a significant clinical effect on advanced esophageal cancer.Compared with paclitaxel and cisplatin alone,combination therapy can increase the effective rate of treatment,reduce the incidence of adverse reactions,and enhance the quality of life of patients.Therefore,carrilizumab combined with paclitaxel and cisplatin may be the preferred treatment for advanced esophageal cancer.
CarelizumabPaclitaxelCisplatinAdvanced esophageal cancer
NETL
NSTL
万方数据
